GU Cancers 2024 | Addition of metastasis-directed therapy in prostate cancer

Giulio Francolini, MD, University of Florence, Florence, Italy, highlights challenges in sequencing therapies in prostate cancer, such as the lack of data and reliable biomarkers. Dr Francolini additionally talks about the need for metastasis-directed therapy to enhance outcomes in patients with metastatic prostate cancer. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.